IBB - ETF AI Analysis
Top Page
iShares Biotechnology ETF (IBB)
Rating:66Neutral
Price Target:―
Positive Factors
Large, Established Biotech Holdings
The fund’s biggest positions include well-known biotech companies, some of which have shown solid gains this year and help support overall performance.
Recent Short-Term Momentum
The ETF has shown strong performance over the past month, suggesting improving sentiment in its biotech holdings despite some recent three-month weakness.
Significant Asset Base
The fund manages a large pool of assets, which can support liquidity and trading efficiency for everyday investors.
Negative Factors
Heavy Sector Concentration
Almost all of the ETF is invested in health care, specifically biotechnology, which increases risk if this single industry faces a downturn.
Mixed Performance Among Top Holdings
Several of the largest positions have shown weak or negative performance this year, which can drag on the fund even as a few names perform strongly.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little protection if the U.S. market or regulatory environment for biotech turns unfavorable.
IBB vs. SPDR S&P 500 ETF (SPY)
AUM9.19B
RegionNorth America
Expense Ratio0.44%
Beta0.76
IssueriShares
Inception DateFeb 05, 2001
Dividend Yield0.22%
Asset ClassEquity
Index TrackedNYSE Biotechnology (TR)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,873,884
30 Day Avg. Volume1,451,031
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
236.55Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering238
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBB Summary
The iShares Biotechnology ETF (IBB) is a fund that follows the NYSE Biotechnology Index, focusing on U.S. biotech companies working on new drugs and medical treatments. It holds well-known names like Gilead Sciences and Amgen, along with many smaller innovators, giving investors a simple way to spread their money across the biotech industry instead of picking individual stocks. Someone might invest in IBB for long-term growth potential tied to medical breakthroughs and new therapies. However, biotech stocks can be very volatile, so the ETF’s price can swing sharply and go up or down quickly.
How much will it cost me?The iShares Biotechnology ETF (IBB) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to track the biotechnology industry. It’s a reasonable cost for the specialized exposure it provides.
What would affect this ETF?The iShares Biotechnology ETF (IBB) could benefit from advancements in medical research, increased demand for innovative treatments, and supportive government policies for health care innovation. However, it may face challenges from regulatory hurdles, high development costs, and potential market volatility tied to interest rate changes or broader economic conditions. Its focus on U.S.-listed biotechnology companies means it is heavily influenced by trends in the U.S. health care sector and the performance of top holdings like Gilead Sciences and Vertex Pharmaceuticals.
IBB Top 10 Holdings
IBB is very much a biotech pure play, with nearly all its firepower aimed at U.S.-listed drug developers. Heavyweights like Vertex and Amgen are doing much of the lifting, with steady-to-rising share prices helping support the fund. On the flip side, Gilead and Regeneron have been losing steam lately, acting as a bit of a brake. The real spark comes from faster climbers like Argenx and Illumina, whose recent rallies add some punch, but the fund remains concentrated in a handful of big biotech names rather than a broad health care mix.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | 8.08% | $734.32M | $114.63B | 5.24% | 78 Outperform | |
| Amgen | 7.83% | $711.36M | $182.21B | 26.53% | 77 Outperform | |
| Gilead Sciences | 6.84% | $621.79M | $153.66B | 17.59% | 78 Outperform | |
| Regeneron | 4.91% | $445.87M | $63.95B | 19.65% | 78 Outperform | |
| Argenx Se | 3.76% | $341.58M | $54.93B | 67.12% | 79 Outperform | |
| Alnylam Pharma | 3.12% | $283.62M | $37.13B | -8.53% | 60 Neutral | |
| Natera | 2.89% | $262.68M | $33.14B | 34.30% | 73 Outperform | |
| Revolution Medicines | 2.78% | $252.66M | $34.65B | 314.11% | 52 Neutral | |
| Biogen | 2.47% | $224.09M | $29.02B | 60.08% | 74 Outperform | |
| Illumina | 2.07% | $188.03M | $24.50B | 78.10% | 71 Outperform |
IBB Technical Analysis
Positive
―
Price Trends
172.54
Positive
171.44
Positive
167.00
Positive
Market Momentum
5.86
Negative
80.24
Negative
96.16
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBB, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 177.36, equal to the 50-day MA of 172.54, and equal to the 200-day MA of 167.00, indicating a bullish trend. The MACD of 5.86 indicates Negative momentum. The RSI at 80.24 is Negative, neither overbought nor oversold. The STOCH value of 96.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBB.
IBB Peer Comparison
Comparison Results
Performance Comparison
IBB
iShares Biotechnology ETF
195.70
67.90
53.13%
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents